Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda.

about

A qualitative evaluation of an implementation study for cryptococcal antigen screening and treatment in Uganda

P2860

Q56910972-716BDCD4-98D1-4214-A15B-E0EB03288893

P2860

Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda.

Item

http://www.wikidata.org/entity/Q36321037

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Cost-effectiveness of CRAG-LFA ...... ple living with HIV in Uganda.

@ast

Cost-effectiveness of CRAG-LFA ...... ple living with HIV in Uganda.

@en

type

Item

label

Cost-effectiveness of CRAG-LFA ...... ple living with HIV in Uganda.

@ast

Cost-effectiveness of CRAG-LFA ...... ple living with HIV in Uganda.

@en

prefLabel

Cost-effectiveness of CRAG-LFA ...... ple living with HIV in Uganda.

@ast

Cost-effectiveness of CRAG-LFA ...... ple living with HIV in Uganda.

@en

P1476

Cost-effectiveness of CRAG-LFA ...... ple living with HIV in Uganda.

@en

P2093

Anu Ramachandran

http://www.w3.org/2001/XMLSchema#string

Maunank Shah

http://www.w3.org/2001/XMLSchema#string

Radha Rajasingham

http://www.w3.org/2001/XMLSchema#string

Yukari Manabe

http://www.w3.org/2001/XMLSchema#string

P2860

Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis

Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV

Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings

Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care

Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast

Q28086855

Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa

Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.

P2888

s12879-017-2325-9

P304

225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12879-017-2325-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084250366

http://www.w3.org/2001/XMLSchema#string

P698

28335769

http://www.w3.org/2001/XMLSchema#string

P921

Uganda

meningitis

P932

5364591

http://www.w3.org/2001/XMLSchema#string

Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda.

about

P2860

P2860

Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932